EUVIMEDEUVIMED entdecken
Crossref

Seroreactivity of antibodies to hepatitis B core antigen among hepatitis B surface antigen‐screened negative blood donors and its implications for blood safety in a resource‐constrained country

Rhoda T Yu, Kenneth Aristotle P Punzalan, Sonu Bhatnagar iD, Raymond B Lutero, Iza Mae S Chamen, Catherine B Masangkay, Elizabeth Y Arcellana-Nuqui

Vox Sanguinis · 2024

DOI: 10.1111/vox.13576 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Vox Sanguinis, 2024. Verfasst von Rhoda T Yu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Research Institute for Tropical Medicine, Muntinlupa City, Philippines. Hauptthemen laut MEDLINE: Hepatitis B Core Antigens, Hepatitis B. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 18 Literaturangaben. Gefördert von: Abbott Laboratories.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives Transfusion‐related hepatitis B infections have been reduced significantly with the implementation of blood screening using both serology and nucleic acid amplification technology (NAT) in developed countries. However, in resource‐constrained countries, where NAT is inaccessible, the risk persists from early acute and occult cases. This study aimed to determine the antibodies to hepatitis B core antigen (anti‐HBc) reactive rate among hepatitis B surface antigen (HBsAg)‐screened negative blood donors and its impact on blood safety in the Philippines. Materials and Methods A total of 1602 HBsAg‐negative samples, randomly collected from nine leading blood service facilities representative of each region in the Philippines, were tested for anti‐HBc immunoglobulin M (IgM), Total and antibodies to HBsAg (anti‐HBs) using the Architect i2000SR Immunoassay Analyser (Abbott Laboratories, IL). Anti‐HBc IgM and/or Total repeat reactive were further tested for hepatitis B virus (HBV) NAT using the Cobas TaqScreen MPX v2.0 (Roche Diagnostics, Basel).

Results

Overall, 19.16% HBsAg‐negative samples ( n = 307/1602) were reactive for either anti‐HBc IgM or Total or a combination of both, of which 1.3% ( n = 4/307) had detectable HBV‐DNA and 80.5% ( n = 247/307) were anti‐HBs positive. About the anti‐HBs titres, 30.27% ( n = 485/1602) were positive (≥10 IU/L) with 55.67% ( n = 270/485) having titres ≥100 IU/L. Anti‐HBs‐only‐positive samples were 14.85% ( n = 238/1602).

Conclusion

We observed a high anti‐HBc reactive rate (19.16%) with 3.7% anti‐HBc‐only reactive (anti‐HBs negative) and 1.3% HBV‐DNA positive. This warrants the need to reconsider existing screening practices to improve blood safety in the country.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B Core AntigensHepatitis BHumansHepatitis B Surface AntigensBlood SafetyBlood DonorsDNA, ViralHepatitis B virusHepatitis B AntibodiesImmunoglobulin M

Stichwörter der Autor:innen

antibodies to HBsAgantibodies to hepatitis B core antigenblood safetyhepatitis Bnucleic acid amplification technologytransfusion-transmitted infections

Substanzen

Hepatitis B Core AntigensHepatitis B Surface AntigensDNA, ViralHepatitis B AntibodiesImmunoglobulin M

Autor:innen und Institutionen

  • Research Institute for Tropical Medicine, Muntinlupa City, Philippines.
  • Abbott Laboratories Singapore Pte Ltd., Singapore.
  • National Council for Blood Services, Department of Health, Manila, Philippines.

ORCID-Profile: Sonu Bhatnagar

Förderung

  • Abbott Laboratories

Zitieren

APA

Yu, R. T., Punzalan, K. A. P., Bhatnagar, S., Lutero, R. B., Chamen, I. M. S., Masangkay, C. B., & Arcellana-Nuqui, E. Y. (2024). Seroreactivity of antibodies to hepatitis B core antigen among hepatitis B surface antigen‐screened negative blood donors and its implications for blood safety in a resource‐constrained country. Vox Sanguinis. https://doi.org/10.1111/vox.13576

Vancouver

Yu RT, Punzalan KAP, Bhatnagar S, Lutero RB, Chamen IMS, Masangkay CB, et al. Seroreactivity of antibodies to hepatitis B core antigen among hepatitis B surface antigen‐screened negative blood donors and its implications for blood safety in a resource‐constrained country. Vox Sanguinis. 2024. doi:10.1111/vox.13576

BibTeX
@article{Yu2024,
  author = {Yu, Rhoda T and Punzalan, Kenneth Aristotle P and Bhatnagar, Sonu and Lutero, Raymond B and Chamen, Iza Mae S and Masangkay, Catherine B and Arcellana-Nuqui, Elizabeth Y},
  title = {Seroreactivity of antibodies to hepatitis B core antigen among hepatitis B surface antigen‐screened negative blood donors and its implications for blood safety in a resource‐constrained country},
  journal = {Vox Sanguinis},
  year = {2024},
  doi = {10.1111/vox.13576}
}
Kostenlos starten →